PHARMACY

Warner Chilcott subsidiary files patent infringement suit

BY Alaric DeArment

HAMILTON, Bermuda A drug maker has filed a patent infringement suit against a generic drug company over its generic version of an antibiotic used to treat acne.

Warner Chilcott announced that Mayne Pharma International, one of its subsidiaries, had filed a lawsuit against Mylan in the District Court for the District of New Jersey for infringement of the ‘161 patent for Doryx (doxycycline) delayed-release tablets in the 150 mg strength. The lawsuit is in response to Mylan’s filing for regulatory approval for a generic version of Doryx before the 2022 expiration of the ‘161 patent.

Warner Chilcott markets Doryx delayed-release tablets in the 75 mg, 100 mg and 150 mg strengths under a license agreement with Mayne.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Investigational oxycodone formulation may discourage drug abusers

BY Alaric DeArment

NEW ORLEANS Two drug companies may have developed a formulation of the painkiller oxycodone that discourages drug abusers.

King Pharmaceuticals and Acura Pharmaceuticals announced Friday that results from an oral abuse liability study of the drug Acurox (oxycodone hydrochloride and niacin) tablets indicate they are disliked among people with a history of opioid abuse, compared with oxycodone tablets alone when they swallow excess doses.

“The fact that people with a history of opioid abuse showed a disliking of Acurox tablets in excessive doses is an indication that the product is an important step in the development of medicines that are designed to deter common methods of abuse, such as over ingestion, while effectively managing pain,” lead study author and chief of Johns Hopkins Bayview Medical Center’s Center for Chemical Dependence Donald Jasinski said.

Results of the study were presented Friday at the American Society of Addiction Medicine’s Medical-Scientific Conference.

The two companies said the Food and Drug Administration had given Acurox priority review classification, and they expect to get a response from the FDA by June 30.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Amylin issues letter to shareholders regarding board of directors

BY Alaric DeArment

SAN DIEGO Drug maker Amylin Pharmaceuticals is urging shareholders to reject prospective members of its board nominated by investor Carl Icahn and Eastbourne Capital Management.

Amylin sent a letter to shareholders Friday, signed by president and CEO Daniel Bradbury and lead independent director James Wilson, requesting that they instead vote for the company’s current board, saying the company was “poised to revolutionize” Type 2 diabetes treatment with the once-weekly formulation of the drug Byetta (exenatide), currently awaiting approval by the Food and Drug Administration. The FDA approved the twice-daily formulation of the drug in 2005.

“To ensure that you benefit from this value opportunity, it is imperative that Amylin has the best possible board of directors,” Bradbury and Wilson wrote in the letter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?